Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in acute severe hypertension cases.
Low-volume, non-weight-based dosing2
CLEVIPREX offers non-weight based dosing that is independent of renal or hepatic function.
Ready-to-use 50 mL and 100 mL vials are available for individualized, titratable administration.
Proven efficacy in clinical studies
- Over 90% of patients with perioperative hypertension achieved treatment success (≥15% BP reduction from baseline)3,4
- Low rate of overshoot in acute severe hypertension patients in the VELOCITY trial5
BP reduction within minutes2
In perioperative patients, CLEVIPREX produces a 4%–5% reduction in systolic blood pressure (SBP) within 2–4 minutes of initiation. An approximately 1–2 mg/hr increase will generally produce an additional 2–4 mmHg decrease in systolic pressure.
Demonstrated safety profile
The safety profile of CLEVIPREX was evaluated in multiple clinical trials.2
CLEVIPREX videos for healthcare professionals
Get access to exclusive videos about CLEVIPREX presented by renowned anesthesiologist Dr. Horowitz.